| 1 |
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth |
|
| | Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty | | | BMC Cancer. 2022; 22(1) | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Hypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathway |
|
| | Xiaoguang Zhou, Peng Zhang, Hu Han, Hongen Lei, Xiaodong Zhang | | | Journal of Cellular Biochemistry. 2019; 120(4): 6471 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Identification of differentially expressed genes and biological pathways in bladder cancer |
|
| | Fucai Tang, Zhaohui He, Hanqi Lei, Yuehan Chen, Zechao Lu, Guohua Zeng, Hangtao Wang | | | Molecular Medicine Reports. 2018; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells |
|
| | Jun-Feng Chen, Bi-Xia Yu, Liang Ma, Xiu-Yi Lv, Jun-Hui Jiang, Qi Ma | | | Oncology Letters. 2018; | | | [Pubmed] [Google Scholar] [DOI] | |
|
